There is a pressing need for a new start in health technology assessment to ensure that the standards for product assessment meet those of the physical and more mature social sciences such as education, psychology, and economics.
To register for this program visit: https://uwyo-erx.my.site.com/uwyoce/s/
Program content developed by:
Dr Paul C Langley, Ph.D., Adjunct Professor College of Pharmacy, University of Minnesota, Minnesota MN and Lecturer, School of Pharmacy, University of Wyoming, Laramie WY
The fundamental premise of this Certificate Program is the need for those involved in health technology assessment to embrace the standards of normal science and fundamental or Rasch measurement. This proposed new start rejects currently accepted standards, notably for those that fail to adequately address claims from patient-reported outcomes and the creation of assumption-driven modelled simulated claims for non-evaluable cost-effectiveness.
The challenge for those who choose to enroll in this Certificate Program is to accept that a rejection of the current belief system in technology assessment is long overdue. Rather than building on false claims and assumptions plucked from the literature, thus ignoring or demonstrating a lack of awareness of the problem of induction, the Certificate Program offers a framework of analysis that focuses on demarcation and falsification of claims; claims that are expressed in terms that meet Rasch measurement standards for single attributes whether the claim is clinical, in terms of PROs or resource allocation and drug utilization, supported in each case by a claims assessment protocol. This provides a meaningful basis for a research strategy to support the discovery of new facts for therapy impact, including meeting perceived evidence gaps over the life cycle of the product as well as the initial submission for new products to formulary committees and other health system decision-makers. This new start in health technology assessment rejects the creation of non-evaluable simulation-modelled imaginary claims for cost-effectiveness which are an analytical dead-end.
The Certificate Program is presented in three parts:
The Certificate Program package includes extensive notes (overall for the 14 modules 85,000 words), audiovisual presentations, and a short true-false and multiple-choice assessment for each module. The modules are designed for those who are looking to a new framework for the evaluation of pharmaceutical products and devices, to support robust value claims, ongoing disease area therapeutic class reviews, and if required, outcomes-based contracting. The cost of the Certificate Program is $875, providing 20.5 hours of ACPE credit. For those not seeking ACPE credit, the University of Wyoming will provide a Certificate of Completion. ACPE # 0653-23-001-CP
The following link to a Working Paper describes the structure and content of the Certificate Program.
https://maimonresearch.com/wp-content/uploads/2024/02/Maimon-Working-Paper-No-22-V2.pdf
If you have questions about this program please connect with Jen Paintin | Program Coordinator | jpaintin@uwyo.edu